Tirzepatide advantages in trials: Greater total weight loss, stronger HbA1c reduction, favorable body composition changes, long-term durability data Semaglutide advantages in trials: Established cardiovascular outcomes data (SELECT trial), longer real-world track record, oral formulation option Both medications: Require lifestyle changes to maximize results
, ,
Resistance training to protect and build muscle while fat levels drop
typically dose-related and diminishing over time Serious risks : Pancreatitis (rare), gallbladder events, thyroid C-cell tumor boxed warning (from rodent studies) Dose escalation : Slow titration (0.25 mg escalating monthly) mitigates GI tolerability Strength : The safety database is massive, with well-defined risk-benefit profile across multiple patient populations Survodutide Side Effects# Less well-characterized with limited clinical exposure: GI effects : Expected GLP-1 class effects (nausea, vomiting, diarrhea) observed in Phase 2 Glucagon-specific concerns : Potential for hepatic glucose output increase (mitigated by GLP-1 component), theoretical impact on blood glucose in diabetic populations Heart rate : Glucagon receptor agonism may affect heart rate
ICSI procedures can be used as long as viable sperm are present in the ejaculate or retrievable from the reproductive tract
